These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1749087)

  • 1. [Mucoid Pseudomonas aeruginosa infection in cystic fibrosis].
    Amitani R; Kuze F
    Nihon Rinsho; 1991 Oct; 49(10):2312-6. PubMed ID: 1749087
    [No Abstract]   [Full Text] [Related]  

  • 2. Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis.
    Govan JR; Harris GS
    Microbiol Sci; 1986 Oct; 3(10):302-8. PubMed ID: 3155268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of a highly prevalent Pseudomonas aeruginosa clone in Dutch cystic fibrosis patients.
    de Vrankrijker AM; Brimicombe RW; Wolfs TF; Heijerman HG; van Mansfeld R; van Berkhout FT; Willems RJ; Bonten MJ; van der Ent CK
    Clin Microbiol Infect; 2011 Mar; 17(3):382-5. PubMed ID: 20807225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of local defense mechanisms in cystic fibrosis.
    Proesmans M; De Boeck K
    Acta Otorhinolaryngol Belg; 2000; 54(3):367-72. PubMed ID: 11082773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis.
    Hoiby N; Flensborg EW; Beck B; Friis B; Jacobsen SV; Jacobsen L
    Scand J Respir Dis; 1977 Apr; 58(2):65-79. PubMed ID: 404701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.
    Faruqi S; McCreanor J; Moon T; Meigh R; Morice AH
    Int J Antimicrob Agents; 2008 Nov; 32(5):461-3. PubMed ID: 18703318
    [No Abstract]   [Full Text] [Related]  

  • 8. Alginate production by the mucoid Pseudomonas aeruginosa associated with cystic fibrosis.
    Gill JF; Deretic V; Chakrabarty AM
    Microbiol Sci; 1987 Oct; 4(10):296-9. PubMed ID: 3155272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients.
    Lee B; Schjerling CK; Kirkby N; Hoffmann N; Borup R; Molin S; Høiby N; Ciofu O
    APMIS; 2011 Apr; 119(4-5):263-74. PubMed ID: 21492226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of multiresistant Pseudomonas aeruginosa infection in cystic fibrosis: how to progress?].
    Burgel PR; Kanaan R
    Rev Mal Respir; 2010 May; 27(5):411-3. PubMed ID: 20569871
    [No Abstract]   [Full Text] [Related]  

  • 11. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS
    APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of the pseudomonas lung lesion in cystic fibrosis.
    Fick RB
    Chest; 1989 Jul; 96(1):158-64. PubMed ID: 2500307
    [No Abstract]   [Full Text] [Related]  

  • 13. Neonatal screening for cystic fibrosis does not affect time to first infection with Pseudomonas aeruginosa.
    Baussano I; Tardivo I; Bellezza-Fontana R; Forneris MP; Lezo A; Anfossi L; Castello M; Aleksandar V; Bignamini E
    Pediatrics; 2006 Sep; 118(3):888-95. PubMed ID: 16950978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between Pseudomonas aeruginosa and host defenses in cystic fibrosis.
    Marshall BC; Carroll KC
    Semin Respir Infect; 1991 Mar; 6(1):11-8. PubMed ID: 1909452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
    Nixon GM; Armstrong DS; Carzino R; Carlin JB; Olinsky A; Robertson CF; Grimwood K
    J Pediatr; 2001 May; 138(5):699-704. PubMed ID: 11343046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cystic fibrosis and pseudomonas aeruginosa current and future strategies].
    Leonard A; Leal T; Lebecque P
    J Pharm Belg; 2007; 62(1):25-8. PubMed ID: 17508664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can mucoid Pseudomonas aeruginosa be eradicated in children with cystic fibrosis?
    McPherson H; Rosenthal M; Bush A
    Pediatr Pulmonol; 2010 Jun; 45(6):566-8. PubMed ID: 20503281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
    Macdonald D; Cuthbertson L; Doherty C; Campana S; Ravenni N; Taccetti G; Govan JR
    J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pseudomonas aeruginosa infection in cystic fibrosis. The importance of early antibiotic therapy].
    Dutau G; Brémont F
    Rev Mal Respir; 1990; 7(3):183-5. PubMed ID: 2114027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.